Mylan gains FDA nod for generic migraine therapy

05/17/2013 | Drug Store News

Mylan received federal approval for its zolmitriptan tablets in two strengths, 2.5 mg and 5 mg. The drug, which addresses acute migraine in adults, is a generic form of Zomig by IPR Pharmaceuticals.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC